We use essential cookies (authentication, your saved goals/stack) by default. With your permission we’ll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies

Los4.2

Losartan Research

Mostly mechanism / observational

607 peer-reviewed studies

What the evidence says

Mostly mechanism / observational

Most Losartan studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.

Most evidence is from high-quality meta-analyses and randomised trials published 1995–2026 with a typical study size of 90 participants.

Based on 605 studies · 17 meta-analyses · 581 RCTs · 401 total participants

Confidence

High confidence

By outcome

Blood pressure & strokeLIFE showed losartan reduced cardiovascular events — driven by fewer strokes — beyond atenolol at equal blood-pressure lowering · Months to years
Mostly mechanism / observational449 studies
Kidney & renal health
Mostly mechanism / observational101 studies
Muscle aging & sarcopenia (animal)
Mostly mechanism / observational57 studies
Aging & healthspan (emerging)
Mostly mechanism / observational17 studies
Safety profile
Mostly mechanism / observational5 studies

Slowing down

Only 23 studies in the last 5 years · Latest meta-analysis: 2020

199520102026

1Meta-Analysis2002

Elmfeldt D, Olofsson B, Meredith P · Blood Press (2002)

Losartan Research

Mostly mechanism / observational

The relationships between dose and antihypertensive effect of four AT1-receptor blockers. Differences in potency and efficacy.

The role of losartan in the management of patients with heart failure.

A systematic review and meta-analysis of candesartan and losartan in the management of essential hypertension.

Safety and tolerability of losartan compared with atenolol, felodipine and angiotensin converting enzyme inhibitors.

The effect of losartan on progressive aortic dilatation in patients with Marfan's syndrome: a meta-analysis of prospective randomized clinical trials.

Indirect treatment comparison between fixed-dose-combinations of amlodipine/losartan and amlodipine/valsartan in blood pressure control.

Comparative clinical- and cost-effectiveness of candesartan and losartan in the management of hypertension and heart failure: a systematic review, meta- and cost-utility analysis.

Role of losartan in prevention of aortic dilatation in Marfan syndrome: A systematic review and meta-analysis.

The effects of losartan versus beta-blockers on cardiovascular protection in marfan syndrome: A systematic review and meta-analysis.

Comparison of telmisartan versus losartan: meta-analysis of titration-to-response studies.

Comparison of the efficacy of candesartan and losartan: a meta-analysis of trials in the treatment of hypertension.

Meta-analysis of observed mortality data from all-controlled, double-blind, multiple-dose studies of losartan in heart failure. Losartan Heart Failure Mortality Meta-analysis Study Group.

Enalapril versus losartan for adults with chronic kidney disease: a systematic review and meta-analysis.

Angiotensin II antagonists for hypertension: are there differences in efficacy?

A meta-analysis of randomized trials of telmisartan versus losartan for reduction of ambulatory blood pressure.

Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis.

Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension.

The effects of losartan or angiotensin II receptor antagonists on cartilage: a systematic review.

Leveraging precision medicine analytics to optimize inflammation reduction and enhance physical function in older adults

Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial.